Pembrolizumab: all 1,753 studies that test it

Page 10 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2CompletedNCT02733159Phase 2Results posted
• Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by SurgeryCompletedNCT02730546Phase 1/2Results posted
• Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02730130Phase 2Results posted
• A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersCompletedNCT02728830Early Phase 1Results posted
• Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 2Results posted
• Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)CompletedNCT02720068Phase 1Results posted
• Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck CancerCompletedNCT02718820Phase 1/2Results posted
• Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerCompletedNCT02713529Phase 1/2Results posted
• Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02713373Phase 1/2Results posted
• A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AMLCompletedNCT02708641Phase 2Results posted
• APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaTerminatedNCT02706353Phase 1/2Results posted
• Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet ChemotherapyCompletedNCT02705820Phase 2Results posted
• Pembrolizumab and GM-CSF in Biliary CancerCompletedNCT02703714Phase 2Results posted
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)CompletedNCT02702414Phase 2Results posted
• Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)CompletedNCT02702401Phase 3Results posted
• Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant TherapyCompletedNCT02690558Phase 2Results posted
• Pembrolizumab in Anaplastic/Undifferentiated Thyroid CancerCompletedNCT02688608Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)TerminatedNCT02684617Phase 1Results posted
• Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxelCompletedNCT02684461Phase 2Results posted
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)CompletedNCT02681549Phase 2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)CompletedNCT02674061Phase 2Results posted
• Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaActive, not recruitingNCT02673333Phase 2Results posted
• Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder CancerCompletedNCT02662062Phase 2Results posted
• Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLCCompletedNCT02658097Phase 2Results posted
• Pembrolizumab (Keytruda) in Advanced Hepatocellular CarcinomaCompletedNCT02658019Phase 2Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory LymphomasCompletedNCT02650999Phase 1/2Results posted
• Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic CancerCompletedNCT02648282Phase 2Results posted
• Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal CancersCompletedNCT02642809Phase 1Results posted
• Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT02641093Phase 2Results posted
• Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue SarcomasCompletedNCT02636725Phase 2Results posted
• Pembrolizumab and Chemoradiation Treatment for Advanced Cervical CancerCompletedNCT02635360Phase 2Results posted
• Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma PatientsCompletedNCT02632344Phase 2Results posted
• MK-3475 Immunotherapy in Endometrial CarcinomaCompletedNCT02630823Phase 1Results posted
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedNCT02626000Phase 1Results posted
• Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung CancerCompletedNCT02621398Phase 1Results posted
• Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the BladderCompletedNCT02621151Phase 2Results posted
• Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell CarcinomaCompletedNCT02619253Phase 1Results posted
• Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)CompletedNCT02611960Phase 3Results posted
• Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible CisplatinCompletedNCT02609503Phase 2Results posted
• A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian CancerCompletedNCT02608684Phase 2Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT02603887Early Phase 1Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLCCompletedNCT02591615Phase 2Results posted
• Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic AnalysisCompletedNCT02589496Phase 2Results posted
• Dose-escalation Study of Birinapant and Pembrolizumab in Solid TumorsTerminatedNCT02587962Phase 1/2Results posted
• Pembrolizumab and Palliative Radiotherapy in LungCompletedNCT02587455Phase 1Results posted
• Pembrolizumab in Combination With CRT for LA-SCCHNCompletedNCT02586207Phase 1Results posted
• Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial CancerCompletedNCT02581982Phase 2Results posted
• Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)TerminatedNCT02579863Phase 3Results posted
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)CompletedNCT02578680Phase 3Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)CompletedNCT02576990Phase 2Results posted
• Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)TerminatedNCT02576977Phase 3Results posted
• MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer PatientsCompletedNCT02574598Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)CompletedNCT02564263Phase 3Results posted
• A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsCompletedNCT02563548Phase 1Results posted
• Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)CompletedNCT02559687Phase 2Results posted
• Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)CompletedNCT02555657Phase 3Results posted
• Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)TerminatedNCT02553499Phase 1Results posted
• Pembrolizumab and Paclitaxel in Refractory Small Cell Lung CancerCompletedNCT02551432Phase 2Results posted
• Pembro/Carbo/Taxol in Endometrial CancerCompletedNCT02549209Phase 2Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results posted
• Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryCompletedNCT02538510Phase 1/2Results posted
• GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)CompletedNCT02528357Phase 1Results posted
• Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02520154Phase 2Results posted
• Safety Study of a Helper Peptide Vaccine Plus PembrolizumabCompletedNCT02515227Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611CompletedNCT02509507Phase 1/2Results posted
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results posted
• Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)CompletedNCT02504372Phase 3Results posted
• Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)TerminatedNCT02501473Phase 1/2Results posted
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results posted
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
• Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder CancerCompletedNCT02500121Phase 2Results posted
• Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsTerminatedNCT02499952Phase 2Results posted
• Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate CancerCompletedNCT02499835Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)CompletedNCT02494583Phase 3Results posted
• Trial of pIL-12/MK-3475 in Metastatic MelanomaCompletedNCT02493361Phase 2Results posted
• Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate CancerCompletedNCT02489357Not applicableResults posted
• Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)CompletedNCT02460198Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)CompletedNCT02453594Phase 2Results posted
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsTerminatedNCT02452424Phase 1/2Results posted
• A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLCCompletedNCT02451930Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)CompletedNCT02447003Phase 2Results posted
• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results posted
• Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian CancerCompletedNCT02440425Phase 2Results posted
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)CompletedNCT02437136Phase 1/2Results posted
• A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced MelanomaCompletedNCT02434354Phase 1Results posted
• MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02422381Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyActive, not recruitingNCT02411656Phase 2Results posted
• Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLCCompletedNCT02407171Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Malignant MesotheliomaCompletedNCT02399371Phase 2Results posted
• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCTerminatedNCT02382406Phase 1/2Results posted
• Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal CancerCompletedNCT02375672Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)CompletedNCT02370498Phase 3Results posted
• Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibCompletedNCT02364609Phase 1Results posted
• Pembrolizumab and Epacadostat in Patients With Thymic CarcinomaStatus unknownNCT02364076Phase 2Results posted

← Pembrolizumab overview